一项随机、双盲、安慰剂对照、重复剂量的中试研究,研究了基于大麻二酚(CBD)和大麻二醇(CBG)的饮料粉末的安全性、耐受性和初步效果,以支持从迟发性肌肉酸痛(DOMS)中恢复。

IF 4.5 2区 医学 Q1 NUTRITION & DIETETICS
Erica N Peters, Helena Yardley, Amy Harrison, Graham M L Eglit, Jose Antonio, Cynthia Turcotte, Marcel O Bonn-Miller
{"title":"一项随机、双盲、安慰剂对照、重复剂量的中试研究,研究了基于大麻二酚(CBD)和大麻二醇(CBG)的饮料粉末的安全性、耐受性和初步效果,以支持从迟发性肌肉酸痛(DOMS)中恢复。","authors":"Erica N Peters, Helena Yardley, Amy Harrison, Graham M L Eglit, Jose Antonio, Cynthia Turcotte, Marcel O Bonn-Miller","doi":"10.1080/15502783.2023.2280113","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cannabinoid-containing products are marketed to athletes as promoting recovery, in spite of a lack of data on their safety and effects. This randomized, double-blind, placebo-controlled, repeated-dose pilot study tested the safety, tolerability, and preliminary effects on recovery of a formulation containing cannabidiol (CBD; 35 mg), cannabigerol (CBG; 50 mg), beta caryophyllene (BCP; 25 mg), branched-chain amino acids (BCAAs; 3.8 g), and magnesium citrate (420 mg).</p><p><strong>Methods: </strong>Exercise-trained individuals (<i>N</i> = 40) underwent an experimental induction of delayed onset muscle soreness (DOMS) and completed follow-up visits 24-, 48-, and 72-hours post-DOMS. Participants were randomized to active or placebo formulation, and consumed the formulation twice per day for 3.5 days.</p><p><strong>Results: </strong>There was one adverse event (AE) in the active group (diarrhea) and two AEs in placebo (dry mouth; eye rash/swollen eye). There was 100% self-reported compliance with formulation consumption across the two groups. For the primary outcome of interest, the estimate of effect for ratings of average soreness/discomfort 72 hours post-DOMS between active and placebo groups was -1.33 (85% confidence interval = -2.55, -0.10), suggesting moderate evidence of a treatment difference. The estimate of effect for the outcome of ratings of interference of soreness, discomfort, or stiffness on daily activities at work or home 48 hours post-DOMS was -1.82 (95% confidence interval = -3.64, -0.01), indicating a treatment difference of potential clinical importance. There was no significant effect between active and placebo groups on objective measures of recovery, sleep quality, or mood disturbance.</p><p><strong>Conclusions: </strong>The tested formulation reduced interference of DOMS on daily activities, demonstrating its improvement on a functional aspect of recovery.</p>","PeriodicalId":17400,"journal":{"name":"Journal of the International Society of Sports Nutrition","volume":"20 1","pages":"2280113"},"PeriodicalIF":4.5000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653658/pdf/","citationCount":"0","resultStr":"{\"title\":\"A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS).\",\"authors\":\"Erica N Peters, Helena Yardley, Amy Harrison, Graham M L Eglit, Jose Antonio, Cynthia Turcotte, Marcel O Bonn-Miller\",\"doi\":\"10.1080/15502783.2023.2280113\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cannabinoid-containing products are marketed to athletes as promoting recovery, in spite of a lack of data on their safety and effects. This randomized, double-blind, placebo-controlled, repeated-dose pilot study tested the safety, tolerability, and preliminary effects on recovery of a formulation containing cannabidiol (CBD; 35 mg), cannabigerol (CBG; 50 mg), beta caryophyllene (BCP; 25 mg), branched-chain amino acids (BCAAs; 3.8 g), and magnesium citrate (420 mg).</p><p><strong>Methods: </strong>Exercise-trained individuals (<i>N</i> = 40) underwent an experimental induction of delayed onset muscle soreness (DOMS) and completed follow-up visits 24-, 48-, and 72-hours post-DOMS. Participants were randomized to active or placebo formulation, and consumed the formulation twice per day for 3.5 days.</p><p><strong>Results: </strong>There was one adverse event (AE) in the active group (diarrhea) and two AEs in placebo (dry mouth; eye rash/swollen eye). There was 100% self-reported compliance with formulation consumption across the two groups. For the primary outcome of interest, the estimate of effect for ratings of average soreness/discomfort 72 hours post-DOMS between active and placebo groups was -1.33 (85% confidence interval = -2.55, -0.10), suggesting moderate evidence of a treatment difference. The estimate of effect for the outcome of ratings of interference of soreness, discomfort, or stiffness on daily activities at work or home 48 hours post-DOMS was -1.82 (95% confidence interval = -3.64, -0.01), indicating a treatment difference of potential clinical importance. There was no significant effect between active and placebo groups on objective measures of recovery, sleep quality, or mood disturbance.</p><p><strong>Conclusions: </strong>The tested formulation reduced interference of DOMS on daily activities, demonstrating its improvement on a functional aspect of recovery.</p>\",\"PeriodicalId\":17400,\"journal\":{\"name\":\"Journal of the International Society of Sports Nutrition\",\"volume\":\"20 1\",\"pages\":\"2280113\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653658/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the International Society of Sports Nutrition\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/15502783.2023.2280113\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/11/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International Society of Sports Nutrition","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15502783.2023.2280113","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0

摘要

背景:尽管缺乏有关其安全性和效果的数据,但含有大麻酚的产品被销售给运动员,以促进康复。这项随机、双盲、安慰剂对照、重复剂量的中试研究测试了含有大麻二酚(CBD;35 mg)、大麻酚(CBG;50 mg)、β-石竹烯(BCP;25 mg)、支链氨基酸(BCAAs;3.8 g) ,和柠檬酸镁(420 mg)。方法:经过锻炼的个体(N = 40)接受了延迟性肌肉酸痛(DOMS)的实验诱导,并在DOMS后24、48和72小时完成了随访。参与者被随机分为活性制剂或安慰剂制剂,每天服用两次,每次3.5 天。结果:活性组有一例不良事件(AE)(腹泻),安慰剂组有两例不良事件。两组患者对制剂消费的依从性均为100%。对于感兴趣的主要结果,平均疼痛/不适评分的效果估计72 活动组和安慰剂组在DOMS后的小时数为-1.33(85%置信区间 = -2.55,-0.10),表明存在治疗差异的中度证据。疼痛、不适或僵硬对工作或家庭日常活动干扰评级结果的影响估计48 DOMS后的小时数为-1.82(95%置信区间 = -3.64,-0.01),表明具有潜在临床重要性的治疗差异。活性组和安慰剂组在恢复、睡眠质量或情绪障碍的客观指标上没有显著影响。结论:受试制剂减少了DOMS对日常活动的干扰,表明其在功能恢复方面有所改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS).

Background: Cannabinoid-containing products are marketed to athletes as promoting recovery, in spite of a lack of data on their safety and effects. This randomized, double-blind, placebo-controlled, repeated-dose pilot study tested the safety, tolerability, and preliminary effects on recovery of a formulation containing cannabidiol (CBD; 35 mg), cannabigerol (CBG; 50 mg), beta caryophyllene (BCP; 25 mg), branched-chain amino acids (BCAAs; 3.8 g), and magnesium citrate (420 mg).

Methods: Exercise-trained individuals (N = 40) underwent an experimental induction of delayed onset muscle soreness (DOMS) and completed follow-up visits 24-, 48-, and 72-hours post-DOMS. Participants were randomized to active or placebo formulation, and consumed the formulation twice per day for 3.5 days.

Results: There was one adverse event (AE) in the active group (diarrhea) and two AEs in placebo (dry mouth; eye rash/swollen eye). There was 100% self-reported compliance with formulation consumption across the two groups. For the primary outcome of interest, the estimate of effect for ratings of average soreness/discomfort 72 hours post-DOMS between active and placebo groups was -1.33 (85% confidence interval = -2.55, -0.10), suggesting moderate evidence of a treatment difference. The estimate of effect for the outcome of ratings of interference of soreness, discomfort, or stiffness on daily activities at work or home 48 hours post-DOMS was -1.82 (95% confidence interval = -3.64, -0.01), indicating a treatment difference of potential clinical importance. There was no significant effect between active and placebo groups on objective measures of recovery, sleep quality, or mood disturbance.

Conclusions: The tested formulation reduced interference of DOMS on daily activities, demonstrating its improvement on a functional aspect of recovery.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of the International Society of Sports Nutrition
Journal of the International Society of Sports Nutrition NUTRITION & DIETETICS-SPORT SCIENCES
CiteScore
8.80
自引率
3.90%
发文量
34
审稿时长
6-12 weeks
期刊介绍: Journal of the International Society of Sports Nutrition (JISSN) focuses on the acute and chronic effects of sports nutrition and supplementation strategies on body composition, physical performance and metabolism. JISSN is aimed at researchers and sport enthusiasts focused on delivering knowledge on exercise and nutrition on health, disease, rehabilitation, training, and performance. The journal provides a platform on which readers can determine nutritional strategies that may enhance exercise and/or training adaptations leading to improved health and performance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信